investing.comAUG 192 min read$ABT

Abbott settles appeal of $495 million infant formula verdict

Abbott Laboratories (ABT) settled an appeal of a $495 million verdict related to its infant formula, according to court documents. The 2024 jury ruling linked the formula to necrotizing enterocolitis (NEC) in a child. Over 1,000 similar lawsuits are pending against Abbott and Mead Johnson (Reckitt). The settlement terms were not disclosed. ABT and Reckitt deny their formulas cause NEC, emphasizing breast milk's protective benefits.

Original reporting

investing.com

Published Aug 19, 2026, 5:54 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 19, 2026, 6:06 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefFinancial news

Primary signal

$ABT

Bullish

high confidence

Mentioned

$ABT

Relevance

8/10

alphai data visualization · based on investing.com

Decision brief

The 30-second read

$ABTBullishMed

Why it matters

The settlement removes a pending $495 million liability, likely stabilizing the stock.

Market read

Legal settlement is material for Abbott; may modestly affect price.

What to watch

Potential future lawsuits beyond the settled case could still pose risk.

Relevance 8/10Novelty 8/10Timing: today

Background

Abbott faces thousands of infant‑formula lawsuits; this settlement resolves one major verdict.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ABTBullishHigh confidence

Context

Abbott Laboratories settled its appeal of a $495 million infant‑formula verdict, a new legal development for the company.

Expected impact

Modest upside as uncertainty is removed; limited short‑term move.

Evidence & confidence

Large settlement amount and removal of appeal risk are material; market likely to price in reduced downside.

Market effects

Sector

May ease concerns for the infant‑formula segment and related healthcare stocks.

Regional

Limited to U.S. healthcare sector; no broader regional effect.

Global

Minimal global impact beyond the company.

Counterpoint

What could challenge this read

Some investors may view the settlement as a sign of lingering legal exposure and stay cautious.

Key entities

company
Abbott Laboratories
US‑listed healthcare company (ticker ABT).

Read at source ← All news

AUG 19

$ABTHighAI 9/10

Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?

Abbott (ABT) reported Q2 2026 sales up 13% (4.8% comparable) and raised its annual profit forecast. Intuitive Surgical (ISRG) saw Q2 revenue grow 19% to $2.89B, with EPS of $2.80. ABT's diagnostics segment grew 42%, while ISRG's robotic surgery ecosystem showed strong margins and system placements. Both companies beat estimates but face different investor concerns.

insidermonkey.com2 min

AUG 13

$SYKMed

Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle

Wolfe Research downgraded Stryker (SYK) to Peer Perform, citing a difficult second-half outlook after a March cyber disruption and noting the June quarter did not fully catch up. Wolfe said Stryker’s guidance implies 54% of revenue in 2H. Wolfe upgraded Abbott (ABT) to Outperform with a $130 target, citing better 2027 catalysts.

investing.com2 min

AUG 11

$ABTMed

Why is Abbott Laboratories stock gaining today?

Abbott Laboratories shares rose about 1.2% in morning trading after the company announced a multi-year collaboration with Google Health. Abbott’s Lingo continuous glucose monitor data will be integrated into the Google Health app, with personalized coaching via Google Health Coach and a large real-world metabolic study. The move was driven by company-specific news amid a flat U.S. market.

investing.com3 min

AUG 10

$JNJMedAI 8/10

Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?

Johnson & Johnson (JNJ) reported fiscal Q2 2026 sales up nearly 7% to $25.31B and adjusted EPS of $2.90, beating estimates. It raised guidance, targeting 2026 annual revenue over $100B for the first time and lifted adjusted EPS midpoint to $11.68. Abbott (ABT) posted Q2 sales up 13% and raised full-year adjusted EPS to $5.45-$5.60.

insidermonkey.com6 min

AUG 4

$ABTMed

Abbott vs Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?

Abbott Laboratories (ABT) reported fiscal Q2 2026 results, with sales up 13% reported and 4.8% comparable, GAAP diluted EPS $0.53 and adjusted $1.31, and raised full-year 2026 adjusted EPS guidance to $5.45-$5.60. Danaher (DHR) posted Q2 revenue $6.3B (+5.5% YoY) and adjusted EPS $1.94 vs $1.83 estimates, but cut full-year core revenue outlook upper end to 4% from 6%.

insidermonkey.com7 min

AUG 3

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

independent.co.uk6 min